Vericel Corporation (VCEL) — closed signal from December 9, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 9, 2026.
Predicted vs. what happened
What happened
Reached 29% of the predicted growth at its peak, without hitting the target.
The thesis — published December 9, 2025
Vericel makes advanced cell therapies and is seen as a high-growth biotech with lots of investor interest, but its price looks high compared to fundamentals. Short-term signals show weakness even though the longer trend is up, so the stock may be pausing after prior gains. Media and analysts point to about 40 percent upside, but biotech risks mean this fits active traders.
Primary drivers
- Short-term technicals look weak while the longer trend remains higher.
- Focus on cell therapies for sports injuries and severe burns in growing niches.
- Press and analysts highlight near 40 percent upside potential.
- Weak fundamental score means keep position size small and cautious.
How it played out
VCEL: target missed after a brief rise
Lyra published VCEL at 37.80 on 2025-12-09 with expected growth of 35%. The thesis pointed to weak short-term technicals, a longer trend that remained higher, cell therapies for sports injuries and severe burns, press and analyst upside near 40%, and a weak fundamental score that called for caution.
Inside the window, VCEL rose to 41.65 on 2026-01-08, a peak gain of 10.2%. It never reached the 51.03 target. By 2026-03-09, it ended at 34.12, below the publication price. The thesis partially played out on the brief rise, but it missed the target and faded by the close.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.